Category Archives: Regional News

You are here: Home » Category: "Regional News"

Spark Therapeutics Announces Positive CHMP Opinion for One-time Gene Therapy LUXTURNA® (voretigene neparvovec) in the European Union

LUXTURNA would be first gene therapy for a genetic disease approved in both U.S. and EU LUXTURNA would be first and only gene therapy approved in EU to treat patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells, a condition leading to…

[Read More]

Aclaris Therapeutics to Attend Upcoming Investor Conferences

WAYNE, Pa., Sept. 21, 2018 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunology, today announced that management will attend the following conference: Dr. Neal Walker, President and Chief Executive Officer, will present…

[Read More]

Supernus to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference

ROCKVILLE, Md., Sept. 20, 2018 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company’s management will present an overview and Company update as well as host investor meetings, at the 2018 Cantor Fitzgerald Global…

[Read More]

Project HOPE Team Responds to Urgent Health Needs as Venezuelans Flee

Millwood, VA, Sept. 20, 2018 (GLOBE NEWSWIRE) — Project HOPE announced today that it is deploying an emergency response team to address an exodus of people fleeing political turmoil and an economic collapse in Venezuela that have contributed to the worst humanitarian crisis in the Western Hemisphere and created dangerous health conditions. The Virginia-based international…

[Read More]

Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

RADNOR, Pa., Sept. 20, 2018 (GLOBE NEWSWIRE) — Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation Committee of the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 42,000 shares…

[Read More]

Helius Announces First Partnership to Implement Clinical Experience Programs With the Investigational PoNS™ Therapy in the United States

NEWTOWN, Pa., Sept. 19, 2018 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that it has partnered with The Ohio State University Wexner Medical Center, a leading U.S. neurorehabilitation center located in Columbus, OH to establish the Company’s first Clinical Experience…

[Read More]

Neuronascent Awarded $2.25 Million NIH Grant to Develop a Regenerative Therapeutic for Alzheimer’s Disease

CLARKSVILLE, Md., Sept. 19, 2018 (GLOBE NEWSWIRE) — Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the National Institute on Aging (NIA), part of the National Institutes of Health, has awarded the company an 18-month R01 award.  The grant award is expected to total just over $2.25 million and will fund the…

[Read More]

Idera Pharmaceuticals Announces Appointment of Howard Pien to its Board of Directors

EXTON, Pa., Sept. 18, 2018 (GLOBE NEWSWIRE) — Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune modulator, tilsotolimod, for the treatment of cancer, today announced that Howard Pien joined its Board of Directors, effective September 18, 2018. Mr. Pien has worked in the pharmaceutical and…

[Read More]